Company / R&D Expense
Serina Therapeutics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$13.2M
FY2025
5-year range
$1.0M / $13.2M
FY2021-FY2025
Trend
+450.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense changed +451% YoY in FY2025, a notable deviation from the 6-year average annual change of +80%.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of +17.4%.
Improved from $2M to $13M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +134.1%
- 5-Year CAGR
- +17.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.4%, indicating consistent growth.
- In FY2025, r&d expense increased 450.9% year-over-year.
- Lowest r&d expense in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.2M | +450.9% |
| FY2024 | $2.4M | +0.0% |
| FY2023 | $2.4M | +133.0% |
| FY2022 | $1.0M | -29.6% |
| FY2021 | $1.5M | -75.3% |
| FY2020 | $5.9M | +1.3% |
| FY2018 | $5.8M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026